<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003682</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066784</org_study_id>
    <secondary_id>FRE-FNCLCC-GETUG-02</secondary_id>
    <secondary_id>EU-98058</secondary_id>
    <nct_id>NCT00003682</nct_id>
  </id_info>
  <brief_title>Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer</brief_title>
  <official_title>Treatment of Metastatic Prostate Cancer That is Hormone-Independent: Evaluation of the Role of Chemotherapy on the Quality of Life of Patients. Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to make cancer cells stop dividing
      so they stop growing or die. Combining chemotherapy with corticosteroids may be an effective
      treatment for prostate cancer.

      PURPOSE: Randomized phase III trial to compare the effectiveness of methylprednisolone with
      or without doxorubicin in treating patients who have metastatic prostate cancer that has not
      responded to hormone therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the effect of weekly doxorubicin on the quality of life of patients
      with metastatic, hormone-refractory, symptomatic prostate cancer. II. Determine the
      contribution of this treatment on control of pain in these patients. III. Determine the
      toxicity of this regimen in these patients. IV. Determine the objective response and
      biological observations in these patients after this treatment. V. Determine the effect of
      this regimen on survival of these patients.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two
      treatment arms. Arm I: Patients receive methylprednisolone IV weekly for 3 months. Arm II:
      Patients receive methylprednisolone IV and doxorubicin IV weekly for 3 months. Quality of
      life is assessed before treatment, every 4 weeks during treatment, and then every 3 months.
      Patients are followed every 3 months.

      PROJECTED ACCRUAL: A total of 160 patients will be accrued for this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of inclusions
  </why_stopped>
  <start_date>October 1998</start_date>
  <completion_date type="Actual">March 2001</completion_date>
  <primary_completion_date type="Actual">March 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven, symptomatic prostate cancer Appearance or
        aggravation of clinical symptoms with progression of disease Bone pain OR Urethral
        compression OR 20% decrease in performance status Metastatic disease Local-regional or
        distant secondary tumors Documented radiologically or scintigraphically Hormone-refractory
        as defined by progression while on hormone treatment (simple castration or complete
        androgen blockage) Progressive disease No urethral or cervical stenosis Increase of greater
        than 25% prostatic volume on endorectal echography No documentation by PSA increase or
        imagery only Hormone castration verified by testosterone less than 0.5 ng/mL No history of
        CNS metastases

        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 60-100% Life
        expectancy: No specified Hematopoietic: Neutrophil count greater than 1500/mm3 Platelet
        count greater than 100,000/mm3 Hemoglobin greater than 9 g/dL Hepatic: Bilirubin less than
        1.5 times normal Renal: Creatinine less than 1.6 mg/dL Cardiovascular: Ventricular ejection
        fraction at least 50% Other: No contraindication to anthracycline treatment No prior
        primary cancer except basal cell skin cancer

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Arm I: No concurrent chemotherapy Endocrine therapy: At least 1 month since
        prior hormone therapy, including estramustine, except LHRH agonists, which continue Arm I:
        No concurrent estramustine Radiotherapy: At least 3 months since prior strontium 89 No
        concurrent strontium Surgery: See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane Culine, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut du Cancer de Montpellier - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lute Contre le Cancer,Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Nantes - Atlantique</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. - Hopital Gaston Doumergue</name>
      <address>
        <city>Nimes</city>
        <zip>30006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35064</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92211</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General de Saint Nazaire</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2004</study_first_posted>
  <last_update_submitted>June 22, 2016</last_update_submitted>
  <last_update_submitted_qc>June 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

